2015 Antineoplastics

STIs that target Bcr-Abl and EGFR

Comparison

IMATINIB (CML)
GEFITINIB (NSCLC)
Understanding of the genetic defects
Excellent
Poor
Homogeneity of disease process among candidate patients ("likely responders")
Yes, among patients in chronic phase
No
Uniqueness of drug target
(molecular markers)
Only in cancer cells
In many normal and cancer cells
Large scale success
Yes
Not really
(fails more often than it works)

 

Email: Dr. Janet Fitzakerley | ©2015 University of Minnesota Medical School Duluth | Last modified: 11-apr-15 9:39 AM